Reimbursement Of Commercialization Related Expenses — Revenue
Regeneron Pharmaceuticals Reimbursement Of Commercialization Related Expenses — Revenue decreased by 4.9% to $184.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.6%, from $159.20M to $184.10M. Over 4 years (FY 2021 to FY 2025), Reimbursement Of Commercialization Related Expenses — Revenue shows an upward trend with a 22.8% CAGR.
Analysis
How to read this metric
An increase suggests higher shared commercial activity or a shift in the cost-sharing structure of a partnership, while a decrease may indicate reduced collaborative marketing efforts or changes in contractual reimbursement terms.
Detailed definition
This metric represents revenue recognized from the reimbursement of costs incurred by the company for commercializing pr...
Peer comparison
Similar to 'collaboration revenue' or 'cost-sharing revenue' found in other biopharmaceutical companies with significant R&D and commercial partnerships, such as those with co-promotion agreements.
regn_segment_reimbursement_of_commercialization_related_expenses_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $78.30M | $79.00M | $102.80M | $91.70M | $110.80M | $108.60M | $126.30M | $117.60M | $130.90M | $135.50M | $150.40M | $139.50M | $150.80M | $169.00M | $196.10M | $159.20M | $194.00M | $182.60M | $193.50M | $184.10M |
| QoQ Change | — | +0.9% | +30.1% | -10.8% | +20.8% | -2.0% | +16.3% | -6.9% | +11.3% | +3.5% | +11.0% | -7.2% | +8.1% | +12.1% | +16.0% | -18.8% | +21.9% | -5.9% | +6.0% | -4.9% |
| YoY Change | — | — | — | — | +41.5% | +37.5% | +22.9% | +28.2% | +18.1% | +24.8% | +19.1% | +18.6% | +15.2% | +24.7% | +30.4% | +14.1% | +28.6% | +8.0% | -1.3% | +15.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue?
- Regeneron Pharmaceuticals (REGN) reported reimbursement of commercialization related expenses — revenue of $184.10M in Q1 2026.
- How has Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue changed year-over-year?
- Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue increased by 15.6% year-over-year, from $159.20M to $184.10M.
- What is the long-term trend for Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue has grown at a 22.8% compound annual growth rate (CAGR), from $320.50M to $729.30M.
- What does reimbursement of commercialization related expenses — revenue mean?
- Revenue earned by recovering commercialization costs from collaboration partners.